• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Director Hasler Hans Peter

    12/6/24 5:45:11 PM ET
    $NERV
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $NERV alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    HASLER HANS PETER

    (Last) (First) (Middle)
    C/O MINERVA NEUROSCIENCES, INC.
    1500 DISTRICT AVENUE

    (Street)
    BURLINGTON MA 01803

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Minerva Neurosciences, Inc. [ NERV ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    12/05/2024
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock Option (right to buy)(1) $2.12 12/05/2024 A 12,500 (2) 12/04/2034 Common Stock 12,500 $0 12,500 D
    Explanation of Responses:
    1. This option is granted to non-employee directors in accordance with the Company's compensation program for non-employee directors, which provides that each non-employee director is eligible to receive an annual option grant to purchase 12,500 shares of common stock per year.
    2. The shares subject to this option vest in four equal quarterly installments at a rate of 1/4 of the total number of shares every three months, with the first 1/4 vesting on the date that is three months following December 5, 2024 and an additional 1/4 every three months thereafter, subject in each case to the continued service of the Reporting Person as a non-employee director as of such vesting date.
    /s/ Marc Recht, Attorney-in-Fact 12/06/2024
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $NERV alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NERV

    DatePrice TargetRatingAnalyst
    3/4/2022$10.00 → $5.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $NERV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • HC Wainwright & Co. reiterated coverage on Minerva Neurosciences with a new price target

      HC Wainwright & Co. reiterated coverage of Minerva Neurosciences with a rating of Buy and set a new price target of $5.00 from $10.00 previously

      3/4/22 6:14:09 AM ET
      $NERV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NERV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Kupfer David

      4 - Minerva Neurosciences, Inc. (0001598646) (Issuer)

      12/6/24 5:45:13 PM ET
      $NERV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Laghrissi-Thode Fouzia

      4 - Minerva Neurosciences, Inc. (0001598646) (Issuer)

      12/6/24 5:45:16 PM ET
      $NERV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Van Heek G Jan

      4 - Minerva Neurosciences, Inc. (0001598646) (Issuer)

      12/6/24 5:45:18 PM ET
      $NERV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NERV
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $NERV
    Leadership Updates

    Live Leadership Updates

    See more

    $NERV
    Financials

    Live finance-specific insights

    See more
    • Minerva Neurosciences Reports First Quarter 2025 Financial Results and Business Updates

      BURLINGTON, Mass., May 13, 2025 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today reported business updates and financial results for the first quarter of 2025 ended on March 31, 2025.    Corporate Update On March 17, 2025, we were formally notified by Nasdaq that we had regained compliance with Nasdaq Listing Rule 5550(b)(3), and as such, will continue to be listed on the Nasdaq Capital Market. Interactions with the FDA continue with the goal of addressing questions raised in the Complete Response Letter (CRL) to our New Drug Application

      5/13/25 7:30:00 AM ET
      $NERV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Business Updates

      BURLINGTON, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today reported business updates and financial results for the fourth quarter and year ended December 31, 2024.    Corporate Update As previously disclosed in the first quarter of 2024, the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) to our New Drug Application (NDA) for roluperidone for the treatment of negative symptoms in patients with schizophrenia. The company continues to have interactions with the FDA with the goal of addressing

      2/25/25 7:00:00 AM ET
      $NERV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Minerva Neurosciences Reports Third Quarter 2024 Financial Results and Business Updates

      BURLINGTON, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today reported business updates and financial results for the third quarter of 2024 ending September 30, 2024.    Roluperidone NDA Update As announced in February 2024, the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) to our New Drug Application (NDA) for roluperidone (f/k/a MIN-101) for the treatment of negative symptoms in patients with schizophrenia. Interactions with the FDA continue with the goal of addressing questions rais

      11/5/24 7:30:00 AM ET
      $NERV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Minerva Neurosciences Announces Promotion of Geoff Race to President

      Frederick Ahlholm is Named Chief Financial Officer as Company Prepares to Submit a Pre-NDA Meeting Request to FDA WALTHAM, Mass., Oct. 11, 2021 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that Geoff Race, current Executive Vice President, Chief Financial Officer and Chief Business Officer of Minerva, has been promoted to President. Minerva's Senior Vice President and Chief Accounting Officer, Frederick Ahlholm, has been promoted to Chief Financial Officer. The appointments are effective immediately. These latest leadership

      10/11/21 8:30:00 AM ET
      $NERV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Minerva Neurosciences Announces Appointment of Dr. Ramana Kuchibhatla as Senior Vice President and Head of Research & Development

      WALTHAM, Mass., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced Dr. Jay Saoud's retirement and transition to an advisory role and Dr. Ramana Kuchibhatla's appointment as Senior Vice President and Head of Research & Development, both effective September 16, 2021. Dr. Kuchibhatla will report directly to Dr. Remy Luthringer, Executive Chairman and Chief Executive Officer of Minerva. "I would like to thank Jay for the invaluable skill and leadership which have enabled Minerva to take roluperidone from early stage cl

      9/8/21 8:30:00 AM ET
      $NERV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Minerva Neurosciences Reports 2023 First Quarter Financial Results and Business Updates

      BURLINGTON, Mass., May 15, 2023 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today reported business updates and financial results for the first quarter ended March 31, 2023. "The first quarter saw the achievement of a significant milestone for our investigational drug, roluperidone, and for Minerva, as the U.S. Food and Drug Administration (FDA) filed our New Drug Application (NDA) for roluperidone for the treatment of negative symptoms of schizophrenia on April 27, 2023. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) goal date of

      5/15/23 7:30:00 AM ET
      $NERV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Minerva Neurosciences to Report First Quarter 2023 Financial Results and Business Updates on May 15, 2023

      BURLINGTON, Mass., May 08, 2023 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will release first quarter 2023 financial results and business updates on Monday, May 15, 2023. The Company will host a webcast that day at 8:30 a.m. Eastern Time to discuss the results and updates. The live conference call may be accessed here and on the Company's website under Events and Presentations. The archived webcast will be available on the Company's website beginning approximately two hours after the event for 90 days. About Miner

      5/8/23 8:30:00 AM ET
      $NERV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Minerva Neurosciences Reports Fiscal Year 2022 Fourth Quarter And Year End Financial Results And Business Updates

      BURLINGTON, Mass., March 08, 2023 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today reported business updates and financial results for the fourth quarter and year ended December 31, 2022. Corporate Update "In 2022, we had multiple interactions with the FDA regarding the regulatory path forward for our lead compound, roluperidone. After submitting an NDA for roluperidone to the FDA in August, we received a Refuse to File letter (RTF) in the fall, which was upheld following another meeting with the FDA. We remain committed to developing roluperid

      3/8/23 7:30:00 AM ET
      $NERV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NERV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Minerva Neurosciences Inc

      SC 13G/A - Minerva Neurosciences, Inc. (0001598646) (Subject)

      11/12/24 10:32:12 AM ET
      $NERV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Minerva Neurosciences Inc

      SC 13G - Minerva Neurosciences, Inc. (0001598646) (Subject)

      2/9/24 9:28:31 AM ET
      $NERV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Minerva Neurosciences Inc (Amendment)

      SC 13G/A - Minerva Neurosciences, Inc. (0001598646) (Subject)

      1/18/24 10:21:16 AM ET
      $NERV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NERV
    SEC Filings

    See more
    • SEC Form 10-Q filed by Minerva Neurosciences Inc

      10-Q - Minerva Neurosciences, Inc. (0001598646) (Filer)

      5/13/25 7:00:34 AM ET
      $NERV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form 10-K/A filed by Minerva Neurosciences Inc

      10-K/A - Minerva Neurosciences, Inc. (0001598646) (Filer)

      4/28/25 6:46:17 PM ET
      $NERV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form 10-K/A filed by Minerva Neurosciences Inc

      10-K/A - Minerva Neurosciences, Inc. (0001598646) (Filer)

      4/21/25 4:55:27 PM ET
      $NERV
      Biotechnology: Pharmaceutical Preparations
      Health Care